Search Results

Synthon Biopharmaceuticals B.V., a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless cancers and autoimmune diseases, announced that it is relaunching as Byondis.

The Supervisory Board of Synthon BV, an international, science-centered pharmaceutical company specialized in developing and manufacturing high-quality generic and hybrid medicines for patients around the world, is pleased to announce that Anish Mehta is appointed as Chief Executive Officer and member of the Board of Directors, effective immediately.

The study will be conducted in the Clinical Research Center of the University of Chicago under the leadership of Dr. Alexandra Dumitrescu, the Principal Investigator.

Mylan N.V. (NASDAQ: MYL) today announced that the Technical Board of Appeal of the European Patent Office (EPO) has held that Yeda Research and Development Compa

Synthonics, Inc., a specialty pharmaceutical company focused on the development of proprietary metal coordinated pharmaceuticals, today announced the results of the first clinical trial of PolyZincLiothyronine (PZL), a novel extended release Liothyronine (LT3) compound for the management of hypothyroidism.

The Exclusive Research Report on Remicade Biosimilar with Industry-Primary Research, Secondary Research, Product Research, Revenue, Emerging Trends and Top Growing Companies 2020-2029″.

Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) today announced that the first cancer patients have started treatment with its investigational antibody-drug conjugate (ADC) SYD1875.

Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) is pleased to announce the appointment of Robbert Van Heekeren as chief financial officer. Mr. Van Heekeren will assume this role on September 1, operating out of Byondis’ headquarters in Nijmegen.